{"url_path":"/sec/mbrx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-017034-index.html","accession_number":"0001437749-26-017034","cik":"0001659617","ticker":"MBRX","issuer_name":"Moleculin Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1659617/0001437749-26-017034-index.html","primary_entity_key":"0001659617","primary_entity_name":"Moleculin Biotech, Inc."},"word_count":558,"has_tables":true,"body_markdown":"**ITEM 6. EXHIBITS**\n\n** **\n\n \n\n**Exhibit No.**\n\n \n\n**Description**\n\n \n \n \n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated by reference to exhibit 3.1 of the Form S-1/A filed March 21, 2016)](http://www.sec.gov/Archives/edgar/data/1659617/000114420416089330/v434611_ex3-1.htm)\n\n \n \n \n\n3.2\n\n \n\n[Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated by reference to Exhibit 3.1 of the Form 8-K filed May 24, 2019)](http://www.sec.gov/Archives/edgar/data/1659617/000165961719000077/exh31moleculin-charteramen.htm)\n\n \n \n \n\n3.3\n\n \n\n[Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated by reference to Exhibit 3.1 of the Form 8-K filed January 29, 2021)](http://www.sec.gov/Archives/edgar/data/1659617/000143774921001530/ex_223281.htm)\n\n \n \n \n\n3.4\n\n \n\n[Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc. (incorporated by reference to Exhibit 3.1 of the Form 8-K filed March 19, 2024)](http://www.sec.gov/Archives/edgar/data/1659617/000143774924008537/ex_641760.htm)\n\n \n \n \n\n3.5\n\n \n\n[Certificate of Amendment to Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc., dated August 21, 2025 (incorporated by reference to Exhibit 3.1 of the Form 8-K filed August 27, 2025)](http://www.sec.gov/Archives/edgar/data/1659617/000143774925027798/ex_857436.htm)\n\n \n \n \n\n3.6\n \n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc., filed with the Secretary of State of the State of Delaware. (incorporated by reference to Exhibit 3.1 of the Form 8-K filed November 28, 2025)](http://www.sec.gov/Archives/edgar/data/1659617/000143774925036488/ex_893490.htm)\n\n \n \n \n\n3.7\n \n[Amended and Restated Bylaws of Moleculin Biotech., Inc. (incorporated by reference to exhibit 3.1 of the Form 8-K filed December 17, 2021)](http://www.sec.gov/ix?doc=/Archives/edgar/data/0001659617/000143774921028903/mbrx20211215_8k.htm)\n\n \n \n \n\n4.1\n\n \n[Form of Series H Warrant (incorporated by reference to Exhibit 4.1 of the Form 8-K filed February 20, 2026)](http://www.sec.gov/Archives/edgar/data/1659617/000143774926004800/ex_922997.htm)\n\n \n \n \n\n10.1\n\n \n[Form of Inducement Letter dated February 19, 2026 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed February 20, 2026)](http://www.sec.gov/Archives/edgar/data/1659617/000143774926004800/ex_922998.htmhttp://www.sec.gov/Archives/edgar/data/1659617/000143774926004800/ex_922998.htm)\n\n \n \n \n\n31.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002](ex_936891.htm)\n\n \n \n \n\n31.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002](ex_936892.htm)\n\n \n \n \n\n32.1*+\n\n \n\n[Certification of Principal Executive Officer Pursuant to Section 18 USC. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex_936893.htm)\n\n \n \n \n\n32.2*+\n\n \n\n[Certification of Principal Accounting and Financial Officer Pursuant to Section 18 USC. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex_936894.htm)\n\n \n \n \n\n101.INS*\n\n \n\nInline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) \n\n \n \n \n\n101.SCH*\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n \n \n \n\n101.CAL*\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n \n \n \n\n101.DEF*\n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n \n \n \n\n101.LAB*\n\n \n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n \n \n \n\n101.PRE*\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n \n \n \n\n104\n\n \n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n \n\n \n\n* Filed herewith.\n\n+ The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.\n\n \n\n19\n\n[Table of Contents](#toc)\n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\nMOLECULIN BIOTECH, INC.\n\n \n \n \n\nDate: May 14, 2026\n\nBy:\n\n/s/ Walter V. Klemp\n\n \n \n\nWalter V. Klemp,\n\n \n \n\nChief Executive Officer and Chairman\n\n(Principal Executive Officer)\n\n \n \n \n\nDate: May 14, 2026\n\nBy:\n\n/s/ Jonathan P. Foster\n\n \n \n\nJonathan P. Foster,\n\n \n \n\nExecutive Vice President & Chief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\n \n\n \n\n20"}